AURKA and small cell lung carcinoma: Owonikoko et al., in a negative randomized phase II trial with paclitaxel in addiction either to alisertib (inhibitor of Aurora A kinase, a regulator of mitosis) or placebo in relapsed SCLC, retrospectively reported better survival in patients with alterations of the genes involved in cell cycle regulation among patients treated with alisertib [25].